Aprotinin
Research News and Information

Sunday, March 21, 2010

Aprotinin abolishes sevoflurane postconditioning by inhibiting nitric oxide production and phosphorylation of protein kinase C-delta and glycogen synthase kinase 3beta.

30 Oct 2009 BACKGROUND: It remains controversial whether aprotinin use during cardiac surgery is cardioprotective or detrimental. In contrast, volatile anesthetics may offer cardioprotection perioperatively. Increased nitric oxide, protein kinase C activation, ... Read more...

A randomized clinical trial investigating the relationship between aprotinin and hypercoagulability in off-pump coronary surgery.

30 Oct 2009 BACKGROUND: Off-pump coronary artery bypass (OPCAB) surgery is associated with a hypercoagulable state in which the platelet thrombin receptor, protease-activated receptor-1 (PAR-1), helps propagate a thrombin burst within saphenous vein grafts. ... Read more...

Bodo sp., a free-living flagellate, expresses divergent proteolytic activities from the closely related parasitic trypanosomatids.

30 Aug 2009 We report the characterization of cell-associated and extracellular peptidases of Bodo sp., a free-living flagellate of the Bodonidae family, order Kinetoplastida, which is considered ancestral to the trypanosomatids. This bodonid isolate is ... Read more...

Latest indexed articles for 'Aprotinin'

These are the very latest articles for this heading:

• Aprotinin abolishes sevoflurane postconditioning by inhibiting nitric oxide production and phosphorylation of protein kinase C-delta and glycogen synthase kinase 3beta. 30 Oct 2009
• A randomized clinical trial investigating the relationship between aprotinin and hypercoagulability in off-pump coronary surgery. 30 Oct 2009
• Bodo sp., a free-living flagellate, expresses divergent proteolytic activities from the closely related parasitic trypanosomatids. 30 Aug 2009
• Pediatric pharmacology in the first year of life. 30 Jul 2009
• Suction, salvage, sutures, and potions: blood management post-aprotinin. 15 Jul 2009
• Effect of low-molecular weight trypsin inhibitor, nafamostat mesilate, on trypsin activity using the pancreatic acinar cells. 29 Jun 2009
• Aprotinin and the risk of thrombotic complications after liver transplantation: a retrospective analysis of 1492 patients. 29 Jun 2009
• eComment: A comparison of the safety of aprotinin and tranexamic acid in cardiac surgery. 29 Jun 2009
• Potential for benefits of aprotinin use to outweigh risks in patients undergoing the Ross procedure. 29 Jun 2009
• The association of renal dysfunction and the use of aprotinin in patients undergoing congenital cardiac surgery requiring cardiopulmonary bypass. 29 Jun 2009
• The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial. 29 Jun 2009
• Simulation of NMR data reveals that proteins' local structures are stabilized by electronic polarization. 22 Jun 2009
• Structure of a serine protease poised to resynthesize a peptide bond. 17 Jun 2009
• Lessons learned in antifibrinolytic therapy: The BART trial. 30 May 2009
• Invited commentary: be prepared to change your mind. 30 May 2009
• Anti-inflammatory effect of aprotinin: a meta-analysis. 30 May 2009
• Serine protease inhibitor aprotinin ameliorates renal injury in a rat model of ischemia-perfusion injury. 30 May 2009
• Aprotinin reduces the antiplatelet effect of clopidogrel. 26 May 2009
• [Aprotinin scintigraphy in amyloidosis] 23 May 2009
• [Can amyloidosis scintigraphy be useful?] 23 May 2009

See a longer list of these articles.

Technical information about 'Aprotinin'

Definition: A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Registry Number: 9087-70-1

Descriptor UI: D007611

Alternative terms: Aprotinin; Bovine Kunitz Pancreatic Trypsin Inhibitor; Bovine Pancreatic Trypsin Inhibitor; Trypsin Inhibitor, Kunitz, Pancreatic; Kallikrein-Trypsin Inactivator; Inactivator, Kallikrein-Trypsin; Kallikrein Trypsin Inactivator; Kunitz Pancreatic Trypsin Inhibitor; Trypsin Inhibitor, Basic, Pancreatic; Basic Pancreatic Trypsin Inhibitor; BPTI, Basic Pancreatic Trypsin Inhibitor; Contrykal; Kontrykal; Kontrikal; Arzneimittelwerk Dresden Brand of Aprotinin; Contrical; Dilmintal; Iniprol; Sanofi Winthrop Brand of Aprotinin; Zymofren; Traskolan; Trasylol; Bayer Brand of Aprotinin; Antilysin; Pulmin;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Pharmacological Action: Trypsin Inhibitors; Serine Proteinase Inhibitors; Hemostatics;

Tree Number: D12.776.083;

Online Note: use APROTININ to search KALLIKREIN-TRYPSIN INACTIVATOR 1966-89

History Note: 90; was KALLIKREIN-TRYPSIN INACTIVATOR 1966-89